Cencora (NYSE:COR) Releases Quarterly Earnings Results, Misses Estimates By $0.05 EPS

Key Points

• Cencora reported Q2 adjusted EPS of $4.75, missing consensus by $0.05, and revenue of $78.36 billion versus ~$81.09 billion, though revenue was up ~3.9% year‑over‑year.
• The company raised its fiscal 2026 adjusted EPS guidance to $17.65–$17.90, generated $1.1B of free cash flow in the quarter, and resumed opportunistic share repurchases targeting a $1B buyback by year‑end.
• Management trimmed consolidated revenue guidance to 4%–6% (from 7%–9%) citing a ~ $2B WAC/IRA price headwind, faster brand conversions and slower GLP‑1 growth, a move that pressured the stock toward its 1‑year low.

Cencora (NYSE:COR - Get Free Report) posted its quarterly earnings data on Wednesday. The company reported $4.75 earnings per share for the quarter, missing the consensus estimate of $4.80 by ($0.05), FiscalAI reports. The firm had revenue of $78.36 billion for the quarter, compared to analyst estimates of $81.09 billion. Cencora had a return on equity of 176.54% and a net margin of 0.50%.The firm's quarterly revenue was up 3.9% on a year-over-year basis. During the same period in the prior year, the company earned $4.42 earnings per share. Cencora updated its FY 2026 guidance to 17.650-17.900 EPS.

Here are the key takeaways from Cencora's conference call:

• Cencora reported adjusted diluted EPS of $4.75 (up 7.5%) in Q2, raised full‑year adjusted EPS guidance to $17.65–$17.90, generated $1.1B of free cash flow in the quarter, and resumed opportunistic share repurchases targeting $1B by calendar‑year end.
• Management emphasized investments in digital transformation and specialty capabilities — launching AI‑supported customer tools, driving a second consecutive quarter of operating income growth in global specialty logistics, and accelerating MSO integration (OneOncology/RCA) to support long‑term specialty growth.
• Consolidated revenue guidance was cut to 4%–6% (from 7%–9%) due to a ~$2B headwind from WAC/IRA price reductions, faster‑than‑expected brand conversions at a large mail‑order customer, slower GLP‑1 growth, and recent customer losses.
• Operating expenses rose 22.5% (driven by the OneOncology acquisition) and net interest expense increased to ~$140M this quarter from acquisition financing, though management expects interest to remain steady in Q3 and modestly decline in Q4 while raising consolidated operating income growth guidance to 12%–14%.

Cencora Stock Performance

Shares of COR traded down $53.89 during mid-day trading on Wednesday, reaching $252.01. The company's stock had a trading volume of 5,433,671 shares, compared to its average volume of 1,387,742. Cencora has a 1-year low of $244.82 and a 1-year high of $377.54. The stock has a market cap of $49.02 billion, a P/E ratio of 30.28, a PEG ratio of 1.42 and a beta of 0.64. The business has a 50-day simple moving average of $332.27 and a two-hundred day simple moving average of $343.21. The company has a current ratio of 0.92, a quick ratio of 0.51 and a debt-to-equity ratio of 3.62.

Institutional Trading of Cencora

Hedge funds have recently made changes to their positions in the business. Kemnay Advisory Services Inc. acquired a new stake in shares of Cencora in the fourth quarter valued at approximately $25,000. Motiv8 Investments LLC acquired a new stake in shares of Cencora in the fourth quarter valued at approximately $29,000. Turning Point Benefit Group Inc. acquired a new stake in shares of Cencora in the third quarter valued at approximately $74,000. DV Equities LLC acquired a new stake in shares of Cencora in the fourth quarter valued at approximately $91,000. Finally, Greenline Wealth Management LLC acquired a new stake in shares of Cencora in the fourth quarter valued at approximately $109,000. 97.52% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on COR. Evercore set a $360.00 price objective on Cencora in a research report on Wednesday, April 8th. Leerink Partners reaffirmed an "outperform" rating on shares of Cencora in a research report on Tuesday, March 17th. Weiss Ratings raised Cencora from a "hold (c+)" rating to a "buy (b)" rating in a research report on Thursday, February 5th. Jefferies Financial Group raised Cencora from an "underperform" rating to a "buy" rating in a research report on Thursday, January 22nd. Finally, Barclays upped their price objective on Cencora from $400.00 to $425.00 and gave the stock an "overweight" rating in a research report on Friday, February 13th. Twelve equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $398.17.

Cencora News Roundup

Here are the key news stories impacting Cencora this week:

• Positive Sentiment: Cencora raised its fiscal 2026 adjusted EPS outlook to $17.65–$17.90 (above prior guide and roughly in line or slightly above consensus), signaling confidence in margin/cash generation. Cencora raises annual profit forecast despite quarterly miss
• Positive Sentiment: Company announced a $1 billion share-repurchase plan to be completed by end of calendar 2026, which supports EPS and signals capital-return priority. Cencora slides 17.6% after fiscal Q2 results miss revenue expectations and highlight near-term headwinds
• Neutral Sentiment: Revenue grew modestly (about +3.8% y/y to ~$78.4B) and adjusted EPS improved year-over-year, showing continued specialty-driven growth despite unit-level pressures. Cencora Reports Fiscal 2026 Second Quarter Results
• Negative Sentiment: Quarterly top-line missed Wall Street expectations ($78.36B vs. ~$81.09B consensus) and adjusted EPS slightly missed consensus ($4.75 vs. $4.80), triggering concern about demand and revenue quality. Cencora (COR) Misses Q2 Earnings and Revenue Estimates
• Negative Sentiment: Management trimmed revenue guidance ($334.2B–$340.6B) below analyst expectations, pointing to slower U.S. Healthcare Solutions sales as branded-drug price cuts, lower volume from a large mail-order client and prior customer losses weighed on results. Cencora Shares Drop on Revenue Outlook Cut
• Negative Sentiment: Market reaction pushed the stock to a 52-week low amid heavy volume; investors are focused on near-term customer/ pricing risks despite the raised EPS guide and buyback. Cencora hits 52-week low after guidance cut

Cencora Company Profile

Cencora NYSE: COR is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company's core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.